$MRNA
Moderna, Inc.

2024 Q4 Form 10-Q Financial Statement

#000168285224000060 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $1.862B $2.811B
YoY Change 1.69% -44.71%
Cost Of Revenue $514.0M $929.0M
YoY Change -77.06% -51.56%
Gross Profit $1.348B $1.882B
YoY Change -428.78% -40.56%
Gross Profit Margin 72.4% 66.95%
Selling, General & Admin $281.0M $470.0M
YoY Change -36.43% 25.33%
% of Gross Profit 20.85% 24.97%
Research & Development $1.137B $1.406B
YoY Change -1.98% 16.1%
% of Gross Profit 84.35% 74.71%
Depreciation & Amortization $51.00M $202.0M
YoY Change -79.27% 152.5%
% of Gross Profit 3.78% 10.73%
Operating Expenses $1.137B $1.876B
YoY Change -1.98% 18.28%
Operating Profit -$70.00M $6.000M
YoY Change -96.52% -99.62%
Interest Expense $88.00M $103.0M
YoY Change 51.72% 37.33%
% of Operating Profit 1716.67%
Other Income/Expense, Net -$12.00M -$39.00M
YoY Change -76.47%
Pretax Income $21.00M $70.00M
YoY Change -101.07% -95.77%
Income Tax $8.000M -$147.0M
% Of Pretax Income 38.1% -210.0%
Net Earnings $13.00M $217.0M
YoY Change -100.36% -85.19%
Net Earnings / Revenue 0.7% 7.72%
Basic Earnings Per Share $0.03
Diluted Earnings Per Share $0.03 $0.55
COMMON SHARES
Basic Shares Outstanding 384.8M shares 384.4M shares 381.3M shares
Diluted Shares Outstanding 399.0M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.867B $8.604B
YoY Change -9.32% -13.11%
Cash & Equivalents $1.644B $2.907B
Short-Term Investments $5.223B $5.697B
Other Short-Term Assets $46.00M $88.00M
YoY Change -52.08% 35.38%
Inventory $412.0M $202.0M
Prepaid Expenses
Receivables $1.564B $892.0M
Other Receivables $272.0M $0.00
Total Short-Term Assets $9.666B $10.33B
YoY Change -10.49% -23.13%
LONG-TERM ASSETS
Property, Plant & Equipment $3.165B $2.658B
YoY Change 16.49% 24.26%
Goodwill $52.00M $52.00M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $23.00M $66.00M
YoY Change -73.26% -99.21%
Other Assets $556.0M $685.0M
YoY Change -15.89% -30.67%
Total Long-Term Assets $6.137B $8.101B
YoY Change -29.06% -34.81%
TOTAL ASSETS
Total Short-Term Assets $9.666B $10.33B
Total Long-Term Assets $6.137B $8.101B
Total Assets $15.80B $18.43B
YoY Change -18.75% -28.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $373.0M $520.0M
YoY Change -24.49% 6.78%
Accrued Expenses $1.376B $1.798B
YoY Change -38.13% -14.42%
Deferred Revenue $379.0M $568.0M
YoY Change -72.38% -72.13%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $30.00M $0.00
YoY Change -80.0% -100.0%
Total Short-Term Liabilities $2.201B $3.015B
YoY Change -49.81% -38.76%
LONG-TERM LIABILITIES
Long-Term Debt $625.0M $575.0M
YoY Change 8.7% -36.95%
Other Long-Term Liabilities $276.0M $256.0M
YoY Change 60.47% 89.63%
Total Long-Term Liabilities $276.0M $256.0M
YoY Change 60.47% 89.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.201B $3.015B
Total Long-Term Liabilities $276.0M $256.0M
Total Liabilities $3.876B $4.572B
YoY Change -35.35% -32.12%
SHAREHOLDERS EQUITY
Retained Earnings $11.17B $13.61B
YoY Change -16.61% -25.73%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.93B $13.85B
YoY Change
Total Liabilities & Shareholders Equity $15.80B $18.43B
YoY Change -18.75% -28.74%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income $13.00M $217.0M
YoY Change -100.36% -85.19%
Depreciation, Depletion And Amortization $51.00M $202.0M
YoY Change -79.27% 152.5%
Cash From Operating Activities -$1.566B $622.0M
YoY Change -2.13% -62.58%
INVESTING ACTIVITIES
Capital Expenditures $151.0M $220.0M
YoY Change 7.86% 139.13%
Acquisitions
YoY Change
Other Investing Activities $872.0M -$318.0M
YoY Change -6.14% -66.74%
Cash From Investing Activities $721.0M -$538.0M
YoY Change -8.62% -48.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.00M -109.0M
YoY Change -118.97% -75.11%
NET CHANGE
Cash From Operating Activities -1.566B 622.0M
Cash From Investing Activities 721.0M -538.0M
Cash From Financing Activities 11.00M -109.0M
Net Change In Cash -834.0M -25.00M
YoY Change -4.03% -114.2%
FREE CASH FLOW
Cash From Operating Activities -$1.566B $622.0M
Capital Expenditures $151.0M $220.0M
Free Cash Flow -$1.717B $402.0M
YoY Change -1.32% -74.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001682852
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2024Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3467528
dei Entity Address Address Line1
EntityAddressAddressLine1
325 Binney Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
714-6500
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MRNA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
823000000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
627000000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
9666000000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
10325000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
2335000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4677000000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2381000000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1945000000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
784000000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
713000000 usd
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81000000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81000000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
556000000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
685000000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1798000000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
379000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
568000000 usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
4000000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
63000000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
69000000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
66000000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2201000000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3015000000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
95000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
83000000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
679000000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
643000000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
625000000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
575000000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
276000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
256000000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3876000000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4572000000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
385000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
385000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
382000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
382000000 shares
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-123000000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
11165000000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
13606000000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
514000000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2241000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
725000000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3764000000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1137000000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1160000000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3421000000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3439000000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
281000000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
442000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
823000000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1079000000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
1932000000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
3843000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
4969000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
8282000000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-70000000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2012000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2699000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4245000000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
103000000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
105000000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
334000000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
318000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
919000000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
13000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3630000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2441000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4931000000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.89
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.89
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
385000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
381000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
383000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
382000000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
399000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
381000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
383000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
382000000 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
13000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3630000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2441000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4931000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
73000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
46000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
122000000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
115000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-1000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-6000000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-4000000 usd
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-36000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
74000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
151000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
52000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
134000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
159000000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
95000000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6000000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
112000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
82000000 usd
CY2023Q4 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
79000000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
713000000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
436000000 usd
CY2023Q4 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
1149000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25000000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 usd
CY2023Q4 mrna Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
25000000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
643000000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
575000000 usd
CY2023Q4 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
1218000000 usd
CY2023Q4 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
1243000000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
176000000 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Moderna, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2907000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5223000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5697000000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1564000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
892000000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
412000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
202000000 usd
CY2024Q3 us-gaap Assets
Assets
15803000000 usd
CY2023Q4 us-gaap Assets
Assets
18426000000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
373000000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
520000000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1376000000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
751000000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371000000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1862000000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1831000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2270000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4037000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-58000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-85000000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1958000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2423000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4012000000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1672000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
52000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
126000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
82000000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3578000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2307000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4772000000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
11712000000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2953000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22000000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-51000000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2928000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3217000000 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity File Number
EntityFileNumber
001-38753
CY2024Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
-8000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
0 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
8000000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13455000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13854000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2441000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
325000000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
129000000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
76000000 usd
us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
-43000000 usd
mrna Deferred Income Tax Expense Benefit Net
DeferredIncomeTaxExpenseBenefitNet
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
672000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
147000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
208000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-103000000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-415000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-177000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-58000000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
33000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3829000000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
4641000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4648000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3010000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
529000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2488000000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
55000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
mrna Finance Lease Principal Payments Net Of Adjustments
FinanceLeasePrincipalPaymentsNetOfAdjustments
-4000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59000000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
384817811 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1644000000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
11927000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13854000000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15803000000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18426000000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
13000000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
11927000000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16949000000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
77000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
52000000 usd
CY2023Q3 mrna Stock Repurchased During Period Including Excise Tax Value
StockRepurchasedDuringPeriodIncludingExciseTaxValue
1000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3630000000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
16000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
325000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
134000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2441000000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
11927000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19123000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
12000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
226000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
159000000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1153000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4931000000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13455000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4931000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
226000000 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
419000000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
41000000 usd
us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
-16000000 usd
mrna Deferred Income Tax Expense Benefit Net
DeferredIncomeTaxExpenseBenefitNet
934000000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
481000000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-772000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-462000000 usd
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
63000000 usd
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
657000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8000000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
63000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1173000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
8000000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
605000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
21000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3740000000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
2097000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4711000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2725000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
487000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
85000000 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
23000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4744000000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
31000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1153000000 usd
mrna Finance Lease Principal Payments Net Of Adjustments
FinanceLeasePrincipalPaymentsNetOfAdjustments
146000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1268000000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1000000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1281000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-264000000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1647000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
78000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
148000000 usd
mrna Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments
RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
0 usd
mrna Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments
RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
213000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
75000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
CY2024Q3 mrna Number Of Development Candidates
NumberOfDevelopmentCandidates
36 candidate
CY2024Q3 mrna Number Of Development Programs
NumberOfDevelopmentPrograms
45 developmentprogram
CY2024Q3 mrna Number Of Development Programs Under Clinical Studies
NumberOfDevelopmentProgramsUnderClinicalStudies
42 developmentprogram
us-gaap Use Of Estimates
UseOfEstimates
We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
30000000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
82000000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1644000000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2932000000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
17000000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3000000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4000000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1647000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2953000000 usd
CY2020Q2 mrna Number Of Participants
NumberOfParticipants
30000 participant
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
5240000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
5223000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
2337000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2335000000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
7577000000 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
7558000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
5751000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
5697000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
4768000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
4677000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10519000000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
10374000000 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
887000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
33000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
3578000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
34000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
4465000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
4000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1369000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
147000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
6644000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
151000000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
8013000000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
233 security
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
392 security
CY2024Q3 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-8000000 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-43000000 usd
CY2023Q3 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-33000000 usd
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-16000000 usd
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
42000000 usd
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
171000000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
163000000 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
95000000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15000000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
146000000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
24000000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
412000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
202000000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
65000000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
170000000 usd
CY2024Q3 us-gaap Inventory Write Down
InventoryWriteDown
214000000 usd
us-gaap Inventory Write Down
InventoryWriteDown
302000000 usd
CY2023Q3 us-gaap Inventory Write Down
InventoryWriteDown
1300000000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1900000000 usd
us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
21000000 usd
CY2024Q3 us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
21000000 usd
CY2023Q3 us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
0 usd
us-gaap Inventory Firm Purchase Commitment Loss
InventoryFirmPurchaseCommitmentLoss
141000000 usd
CY2024Q3 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
21000000 usd
CY2023Q4 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
79000000 usd
CY2024Q3 us-gaap Inventory Gross
InventoryGross
477000000 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
372000000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
2932000000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
2378000000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
551000000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
433000000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2381000000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1945000000 usd
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
126000000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
246000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
414000000 usd
CY2024Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
2732000000 usd
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
1584000000 usd
CY2024Q3 mrna Accounts Receivable Chargebacks Discounts And Fees
AccountsReceivableChargebacksDiscountsAndFees
-1168000000 usd
CY2023Q4 mrna Accounts Receivable Chargebacks Discounts And Fees
AccountsReceivableChargebacksDiscountsAndFees
-692000000 usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
1564000000 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
892000000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
286000000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
182000000 usd
CY2024Q3 mrna Other Prepaid Expense Materials And Supplies
OtherPrepaidExpenseMaterialsAndSupplies
193000000 usd
CY2023Q4 mrna Other Prepaid Expense Materials And Supplies
OtherPrepaidExpenseMaterialsAndSupplies
168000000 usd
CY2024Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
105000000 usd
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
19000000 usd
CY2024Q3 mrna Collaboration Receivable Current
CollaborationReceivableCurrent
99000000 usd
CY2023Q4 mrna Collaboration Receivable Current
CollaborationReceivableCurrent
61000000 usd
CY2024Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
50000000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
59000000 usd
CY2024Q3 us-gaap Prepaid Taxes
PrepaidTaxes
26000000 usd
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
0 usd
CY2024Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
18000000 usd
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
50000000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
46000000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
88000000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
823000000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
627000000 usd
CY2024Q3 mrna Downpayments And Prepayments Noncurrent
DownpaymentsAndPrepaymentsNoncurrent
355000000 usd
CY2023Q4 mrna Downpayments And Prepayments Noncurrent
DownpaymentsAndPrepaymentsNoncurrent
342000000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
65000000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
170000000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
52000000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
52000000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44000000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
23000000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
66000000 usd
CY2024Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
20000000 usd
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
11000000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
556000000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
685000000 usd
CY2024Q3 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
403000000 usd
CY2023Q4 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
556000000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
244000000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
245000000 usd
CY2024Q3 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
177000000 usd
CY2023Q4 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
137000000 usd
CY2024Q3 mrna Accrued Manufacturing
AccruedManufacturing
137000000 usd
CY2023Q4 mrna Accrued Manufacturing
AccruedManufacturing
167000000 usd
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
92000000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
122000000 usd
CY2024Q3 mrna Accrued Development Operation
AccruedDevelopmentOperation
80000000 usd
CY2023Q4 mrna Accrued Development Operation
AccruedDevelopmentOperation
140000000 usd
CY2024Q3 mrna Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
78000000 usd
CY2023Q4 mrna Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
94000000 usd
CY2024Q3 mrna Raw Materials Accounts Payable
RawMaterialsAccountsPayable
57000000 usd
CY2023Q4 mrna Raw Materials Accounts Payable
RawMaterialsAccountsPayable
27000000 usd
CY2024Q3 mrna Accrued Clinical Trials
AccruedClinicalTrials
51000000 usd
CY2023Q4 mrna Accrued Clinical Trials
AccruedClinicalTrials
175000000 usd
CY2024Q3 mrna Accrued Commercial
AccruedCommercial
36000000 usd
CY2023Q4 mrna Accrued Commercial
AccruedCommercial
56000000 usd
CY2024Q3 mrna Legal Contingency Future Firm Purchase Commitments
LegalContingencyFutureFirmPurchaseCommitments
21000000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1376000000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1798000000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
30000000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25000000 usd
CY2024Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
18000000 usd
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
41000000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
69000000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
66000000 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
241000000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
235000000 usd
CY2024Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
35000000 usd
CY2023Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
21000000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
276000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
256000000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
651000000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
259000000 usd
mrna Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
436000000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
474000000 usd
CY2024Q3 mrna Operating Lease Number Of Properties
OperatingLeaseNumberOfProperties
2 campus
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
784000000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
498000000 usd
CY2024Q3 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
1282000000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21000000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
30000000 usd
CY2024Q3 mrna Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
51000000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
679000000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
625000000 usd
CY2024Q3 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
1304000000 usd
CY2024Q3 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
1355000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
17000000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
19000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
71000000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
47000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
73000000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
47000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
78000000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
42000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
81000000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
23000000 usd
CY2024Q3 mrna Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
841000000 usd
CY2024Q3 mrna Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
1074000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1161000000 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1252000000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
461000000 usd
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
597000000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000000 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
655000000 usd
CY2024Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
92000000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
110000000 usd
CY2023Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
78000000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
112000000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
77000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
325000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
226000000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
112000000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
77000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
325000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
226000000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
875000000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2024Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21000000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1958000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2423000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4012000000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1672000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
919000000 usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.392
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.855
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.007
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.229
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1700000000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
13000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3630000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2441000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4931000000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
385000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
381000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
383000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
382000000 shares
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14000000 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
399000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
381000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
383000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
382000000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.89
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.89
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11000000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28000000 shares

Files In Submission

Name View Source Status
0001682852-24-000060-index-headers.html Edgar Link pending
0001682852-24-000060-index.html Edgar Link pending
0001682852-24-000060.txt Edgar Link pending
0001682852-24-000060-xbrl.zip Edgar Link pending
exhibit1019302024.htm Edgar Link pending
exhibit3119302024.htm Edgar Link pending
exhibit3129302024.htm Edgar Link pending
exhibit3219302024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrna-20240930.htm Edgar Link pending
mrna-20240930.xsd Edgar Link pending
mrna-20240930_g1.jpg Edgar Link pending
mrna-20240930_g2.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mrna-20240930_cal.xml Edgar Link unprocessable
mrna-20240930_def.xml Edgar Link unprocessable
mrna-20240930_lab.xml Edgar Link unprocessable
mrna-20240930_pre.xml Edgar Link unprocessable
mrna-20240930_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending